Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial
Amylyx Pharmaceuticals has announced positive topline results from the Phase II HELIOS clinical trial, indicating sustained improvements with AMX0035 in…
All articles by RanjithKumar Dharma
RanjithKumar Dharma
-
-
Response begins enrolment for trial of RDX-002 for weight management
Response Pharmaceuticals has initiated subject enrolment for a Phase II trial of its drug candidate RDX-002, designed to manage weight…
-
Innovent’s trial of picankibart for ulcerative colitis meets primary endpoint
Innovent Biologics has reported that its Phase II clinical trial of picankibart (IBI112) in Chinese patients with moderately to severely…
-
Eximia Research acquires Integrated Clinical Trial Services
Integrated clinical trial network Eximia Research has expanded into Iowa, US, with the acquisition of Integrated Clinical Trial Services (ICTS).…
-
Piramal Pharma to expand Lexington sterile injectables facility in US
Piramal Pharma Solutions, a contract development and manufacturing organisation, has announced an $80m investment to expand its sterile injectables facility…
-
Aulos to begin Phase II portion of solid tumour therapy trial
Aulos Bioscience has unveiled plans to begin the Phase II portion of its Phase I/II clinical study of human IgG1…
-
MyMD to begin Phase II trial of rheumatoid arthritis therapy
MyMD Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application…
-
Alentis doses first subject in organ fibrosis therapy trial
Alentis Therapeutics has dosed the first subject in a Phase II clinical study of its investigational monoclonal antibody, lixudebart, to…
-
280Bio doses first subject in oral RAS signalling inhibitor trial
280Bio has dosed the first subject in a Phase I clinical study of oral pan-RAS inhibitor, TEB-17231 (YL-17231), to treat…
-
SciNeuro concludes dosing in study of Alzheimer’s therapeutic
SciNeuro Pharmaceuticals has concluded subject dosing in the Phase I clinical study of its oral therapeutic candidate, SNP318, to treat…